Blue Earth moves toward U.K. prostate radiopharmaceutical licensing

By staff writers

November 9, 2022 -- Blue Earth Therapeutics has secured an "innovation passport" from the U.K.'s Innovative Licensing and Access Pathway (ILAP) for its investigational therapeutic radiopharmaceutical lutetium-177 (Lu-177) rhPSMA-10.1 for treatment of metastatic prostate cancer.

The passport is the entry point to ILAP's process of accelerating time to market for investigational devices. ILAP coordinates a company's interaction with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and the process of submitting marketing authorization applications, Blue Earth said.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking